Biophytis SA, a clinical-stage biotechnology company specialized in the development of drug candidates for treatment of aged related diseases, including neuromuscular diseases, announced a €6.1 million private placement. The capital increase will be completed with the participation of institutional U.S. and European investors. H.C. Wainwright & Co., LLC is acting as the exclusive placement agent…